NewAmsterdam Pharma Co N.V.
No enriched coverage for $NAMS in the last 7 days.
Kastelein Johannes Jacob Pieter (Chief Scientific Officer) sold 125,000 indirectly-held shares of NewAmsterdam Pharma Co N.V. (NAMS) at $26.91 ($3.36M total) on 2026-08-24 under a Rule 10b5-1 trading plan.
NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) appointed Robert W. Gunning, age 55, as its principal
NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q20
Recent NAMS coverage spans insider activity, corporate actions and regulation.
In the last 30 days, NAMS insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($3.4M). The most active reporter was Kastelein Johannes Jacob Pieter, Chief Scientific Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may signal reduced confidence and could exert slight downward pressure on the stock.
This is a governance and finance leadership change with disclosed compensation and start date, but no direct operational or financial guidance.
Regulatory progress in Europe and continued Phase 3 readouts increase probability-weight for upcoming approvals and CVOT/Alzheimer’s catalysts.
Regulatory progress in the EU for obicetrapib can improve approval odds and de-risk the commercialization timeline, supporting risk-on positioning ahead of the European Commission decision.
A positive CHMP opinion is a meaningful de-risking step toward EU commercialization, with potential upside to sales expectations and partner royalty economics.
alphai scores every news story that mentions NAMS with an AI model for sentiment and relevance, and aggregates insider trades from NewAmsterdam Pharma Co N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kastelein Johannes Jacob Pieter (Chief Scientific Officer) sold 125,000 indirectly-held shares of NewAmsterdam Pharma Co N.V. (NAMS) at $26.91 ($3.36M total) on 2026-08-24 under a Rule 10b5-1 trading plan.
1 min readNewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) appointed Robert W. Gunning, age 55, as its principal
2 min readNewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q20
7 min readNewAmsterdam Pharma (NAMS) and Menarini said the EMA CHMP issued a positive opinion for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for adults with primary hypercholesterolemia. CHMP based on Phase 3 BROADWAY, BROOKLYN and TANDEM; LDL-C fell up to 40% with monotherapy and about 50% with the combo vs placebo. European Commission decision expected H2 2026.
3 min readNewAmsterdam Pharma (Nasdaq: NAMS) and Menarini said the EMA CHMP issued a positive opinion recommending marketing authorization in Europe for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM results showing LDL-C reductions up to 40% and about 50%. European Commission decision expected in 2H26.
4 min readNewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001936258 00-0000000 0001936258 us-gaap:CommonStockMember 2026-07-16 2026-07-16 0001936258 us-gaap:WarrantMember 2026-07-16 2026-07-16 0001936258 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursu
2 min readKooij Louise Frederika (Chief Accounting Officer) sold 105,000 shares of NewAmsterdam Pharma Co N.V. (NAMS) at an average of $30.34 ($29.96–$31.71, $3.19M total) across 3 trades on 2026-07-20 under a Rule 10b5-1 trading plan.
1 min readNewAmsterdam Pharma (NAMS) shares fell about 3.8% to $30.465 in mid-day trading, after opening at $31.73 and reaching $32.19, with no new company-specific news cited. The article links the move to profit-taking, risk-off sentiment, and a Q1 2026 institutional filing showing Pictet Asset Management cut its stake by about 99%.
3 min readNewAmsterdam Pharma (Nasdaq: NAMS) said its Compensation Committee approved inducement grants to four new non-executive hires under Nasdaq Rule 5635(c)(4). It granted options for 28,700 ordinary shares with a $35.17 exercise price (July 1, 2026 close) vesting over four years, plus 8,100 RSUs vesting over three years.
2 min readNewAmsterdam Pharma (Nasdaq: NAMS) said it will present at AAIC 2026 in London data on obicetrapib, an oral low-dose CETP inhibitor, for early Alzheimer’s prevention. The company cites a BROADWAY biomarker analysis (n=1,535; ApoE4 carriers n=367) showing lower 12-month p-tau217 changes vs placebo (p=0.025; p=0.022) and says safety was comparable to placebo. PREVAIL enrollment (9,500+ patients) was completed in April 2024.
4 min read
